New perspectives in rheumatology: biomarkers as entry criteria for clinical trials of new therapies for systemic lupus erythematosus: the example of antinuclear …
DS Pisetsky, BH Rovin, PE Lipsky - Arthritis & Rheumatology, 2017 - Wiley Online Library
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease that
represents a great challenge for current therapy as well as new drug development (1, 2) …
represents a great challenge for current therapy as well as new drug development (1, 2) …
[HTML][HTML] Protein and functional isoform levels and genetic variants of the BAFF and APRIL pathway components in systemic lupus erythematosus
P Ortiz-Aljaro, MA Montes-Cano, JR García-Lozano… - Scientific reports, 2022 - nature.com
Systemic lupus erythematosus (SLE) is the prototype of an autoimmune disease.
Belimumab, a monoclonal antibody targets BAFF, is the only biologic approved for SLE and …
Belimumab, a monoclonal antibody targets BAFF, is the only biologic approved for SLE and …
Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus
J Kikuchi, H Hanaoka, S Saito, T Oshige… - …, 2022 - academic.oup.com
Objectives To demonstrate the significance of the time to attain lupus low disease activity
state (LLDAS) after remission induction therapy in patients with severely active SLE …
state (LLDAS) after remission induction therapy in patients with severely active SLE …
[HTML][HTML] The role of belimumab in systemic lupus erythematosis: a systematic review
A Joy, A Muralidharan, M Alfaraj, D Shantharam… - Cureus, 2022 - ncbi.nlm.nih.gov
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple
systems with a range of clinical presentations caused by the production of antibodies …
systems with a range of clinical presentations caused by the production of antibodies …
[HTML][HTML] Lupus-related vasculitis in a cohort of systemic lupus erythematosus patients
SM Gamal, SS Mohamed, M Tantawy… - Archives of …, 2021 - ncbi.nlm.nih.gov
Lupus-related vasculitis in a cohort of systemic lupus erythematosus patients - PMC Back to
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …
[HTML][HTML] Vasculitis in juvenile-onset systemic lupus erythematosus
EMD Smith, H Lythgoe, CM Hedrich - Frontiers in Pediatrics, 2019 - frontiersin.org
Juvenile-onset systemic lupus erythematosus (JSLE) is a rare, heterogeneous multisystem
autoimmune disease that can affect any organ, and present with diverse clinical and …
autoimmune disease that can affect any organ, and present with diverse clinical and …
Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: new aspects
A Nuttall, DA Isenberg - Best practice & research Clinical rheumatology, 2013 - Elsevier
Systemic lupus erythematosus (SLE) is a multisystem auto-immune disorder that results from
a combination of genetic, environmental and hormonal factors. The heterogeneity of disease …
a combination of genetic, environmental and hormonal factors. The heterogeneity of disease …
Development and validation of a risk calculator to differentiate flares from infections in systemic lupus erythematosus patients with fever
S Beça, I Rodríguez-Pintó, MA Alba, R Cervera… - Autoimmunity …, 2015 - Elsevier
Objective To develop and validate a predictive risk calculator algorithm that assesses the
probability of flare versus infection in febrile patients with systemic lupus erythematosus …
probability of flare versus infection in febrile patients with systemic lupus erythematosus …
[HTML][HTML] Risk of systemic lupus erythematosus flares according to autoantibody positivity at the time of diagnosis
OC Kwon, MC Park - Scientific Reports, 2023 - nature.com
To estimate the risk of systemic lupus erythematosus (SLE) flares based on the autoantibody
positivity at the time of SLE diagnosis. This retrospective cohort study included 228 patients …
positivity at the time of SLE diagnosis. This retrospective cohort study included 228 patients …
Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art
CC Mok - Expert review of clinical immunology, 2017 - Taylor & Francis
Introduction: Systemic lupus erythematosus (SLE) is a multi-systemic disease characterized
by an unpredictable disease course and periods of remission and flare, leading to organ …
by an unpredictable disease course and periods of remission and flare, leading to organ …